Diamond Ranch Foods (PLPL) 0.3138 $PLPL
Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company's Production Facility and Start of Commercial Production
ACCESSWIRE - Wed Aug 06, 8:25AM CDT
The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial
Planda Biotechnology, Inc. Provides Shareholder Update on Completion of the Companys Production Facility and Start of Commercial Production
eTeligis - Wed Aug 06, 8:11AM CDT
SEATTLE, WA, United States, via ETELIGIS INC., 08/06/2014 - - Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company's state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.
Plandai Biotechnology, Inc. Announces Support of ICCCO -- the World's First International Cannabis Trade Association
Marketwire - Mon Jul 07, 8:01AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced its support for the formation of the International Coalition of Cannabis Companies and Organizations (ICCCO), the world's first international cannabis trade association co-founded by Plandai director, Jamen Shively. ICCCO was recently formed to deliver on the demands of citizens worldwide: the creation and maintenance of a global cannabis industry, which enforces social responsibility, generates jobs and tax revenues, and ensures consistent standards.
OTC Stocks Daily Trading Focus: Neutra Corporation, Terra Tech Corp, Plandai Biotechnology, Inc. Nano Tech Entertainment, Inc. Techprecision Corp.
PR Newswire Europe - Thu Jul 03, 7:01AM CDT
LONDON, July 3, 2014 /PRNewswire/ --
FDA Exemption Has Plandai Biotechnology Heading Into Third Quarter Ready to Commence Sales of First Phytofare(TM) Product
Marketwire - Thu Jun 26, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently learned that it qualifies for an exemption that will allow the company to commence sales of its Phytofare(TM) Catechin Complex as a dietary supplement without the need to apply to the US Food and Drug Administration (FDA) for approval to market the product.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Shows Over Two Times the Level of Catechins Compared to Generic Extract
Marketwire - Tue Jun 24, 8:15AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received test results from North-West University that indicate that Plandai's Phytofare(TM) Catechin Complex, which is derived from green tea phyto-nutrients, contains 2.2 times the amount of catechins by weight when compared to generic green tea extracts.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Can Be Used as a Dietary Supplement Without Prior FDA Notification or Approval
Marketwire - Wed Jun 18, 7:55AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has received a legal opinion from the noted law firm of Hyman, Phelps & McNamara, P.C., the largest dedicated food and drug legal firm in the country, in which it was determined that Plandai will not be required to apply to the US Food and Drug Administration for approval to market and sell its Phytofare(TM) Catechin Complex as a dietary supplement. This opinion paves the way for Plandai to immediately commence sales efforts in the United States.
OTC Sector Trading Focus List: GrowBlox Sciences, Inc., Amarantus Bioscience Holdings, Inc., Plandai Biotechnology, Inc., Limitless Venture Group, Inc., Infinex Ventures, Inc.
PR Newswire Europe - Wed Jun 11, 5:30AM CDT
LONDON, June 2, 2014 /PRNewswire/ --
Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory
Marketwire - Tue Apr 01, 8:03AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has completed and successfully optimized Stage 2 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Section 2 is the critical stage of the factory's operations as it is in this section that the hydrodynamic sheering process takes place.
Confidential LOI Executed for Unprecedented 'Marijuana Index Fund' - Possible Retracement as The Marijuana Index Dips to $17.95 - 175,000 Jobs Added in February Per US Department of Labor
ACCESSWIRE - Mon Mar 31, 8:09PM CDT
March 31, 2014 / The Marijuana Index - the first and only equity tracking index for marijuana stocks, cannabis stocks, and hemp stocks featuring dynamic financial content, charts, and centralized press for public companies - experienced several significant (positive) events during an otherwise turbulent month (beware the Ides of March, indeed).
Plandai Biotechnology "Waiver" Could Dramatically Expedite Medical Marijuana Research
Marketwire - Mon Mar 31, 8:04AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) has a real opportunity to advance its medical marijuana research, and in doing so, it could be one of the first publicly traded companies in the cannabis industry to reach clinical trials with the drug. While laws in the US still prohibit the advancement of research using marijuana due to its Schedule 1 classification, Plandai's interest in using the drug to discover promising treatments may be about to come to fruition. The company may owe this unexpected opportunity to relationships it has formed on an entirely different continent.
Plandai Biotechnology Management Discusses Progress of Company's Cannabis Extracts
Marketwire - Fri Mar 28, 8:01AM CDT
Last month Plandai Biotechnology, Inc. (OTCQB: PLPL) closed a licensing agreement with Diego Pellicer, Inc. that will allow the company to use the Diego Pellicer name for its Phytofare(TM) cannabis extract in medical and pharmaceutical marijuana applications. Plandai will produce the new Diego Pellicer Gold(TM) extracts in both capsules and cannabis oil (for vapor use) in Pheroid(TM) and non-Pheroid(TM) versions to appeal to the broadest range of medicinal consumers.
Plandai Biotechnology's Human Clinical Trials Offer Significant Proof of Concept
Marketwire - Wed Mar 26, 8:04AM CDT
What may have been lost in Plandai Biotechnology's (OTCQB: PLPL) recently reported results from its human clinical trial to test the anti-aging properties of Phytofare(TM), is that the "statistically significant" results are themselves extremely significant to the future of the company. First and foremost, the results delivered in this human trial using Plandai's Phytofare(TM) Catechin Complex show "proof of concept," and for investors, that proof should turn out to be no small thing when it comes to the future success of this company.
Plandai Biotechnology Reports Positive Human Clinical Trial Results on New Topical Cream
ACCESSWIRE - Mon Mar 24, 8:27AM CDT
Plandai Biotechnology Inc.'s (OTCQB: PLPL), a company that develops heath products from cannabis plant extracts, reported favorable results from a recent human clinical trial involving a topical preparation of its Phytofare(TM) Catechin Complex.
Plandai Biotechnology, Inc. Submits Request to South African Legislature to Permit Cannabis Research
Marketwire - Mon Mar 24, 8:02AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced the submission of a request for ministerial dispensation to the Secretary of Parliament of South Africa to permit cannabis research in South Africa for medicinal purposes. Dr. Mario Oriani-Ambrosini, a South African legislator battling terminal cancer, recently introduced legislation to permit medical marijuana research and usage that has generated a groundswell of popular support and led to the formation of The Cancer Treatment Campaign.
Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company's Production Facility and Start of Commercial Production
ACCESSWIRE - Wed Aug 06, 8:25AM CDT
The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial
Planda Biotechnology, Inc. Provides Shareholder Update on Completion of the Companys Production Facility and Start of Commercial Production
eTeligis - Wed Aug 06, 8:11AM CDT
SEATTLE, WA, United States, via ETELIGIS INC., 08/06/2014 - - Planda Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company's state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.
Plandai Biotechnology, Inc. Announces Support of ICCCO -- the World's First International Cannabis Trade Association
Marketwire - Mon Jul 07, 8:01AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced its support for the formation of the International Coalition of Cannabis Companies and Organizations (ICCCO), the world's first international cannabis trade association co-founded by Plandai director, Jamen Shively. ICCCO was recently formed to deliver on the demands of citizens worldwide: the creation and maintenance of a global cannabis industry, which enforces social responsibility, generates jobs and tax revenues, and ensures consistent standards.
OTC Stocks Daily Trading Focus: Neutra Corporation, Terra Tech Corp, Plandai Biotechnology, Inc. Nano Tech Entertainment, Inc. Techprecision Corp.
PR Newswire Europe - Thu Jul 03, 7:01AM CDT
LONDON, July 3, 2014 /PRNewswire/ --
FDA Exemption Has Plandai Biotechnology Heading Into Third Quarter Ready to Commence Sales of First Phytofare(TM) Product
Marketwire - Thu Jun 26, 8:02AM CDT
Plandai Biotechnology (OTCQB: PLPL) recently learned that it qualifies for an exemption that will allow the company to commence sales of its Phytofare(TM) Catechin Complex as a dietary supplement without the need to apply to the US Food and Drug Administration (FDA) for approval to market the product.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Shows Over Two Times the Level of Catechins Compared to Generic Extract
Marketwire - Tue Jun 24, 8:15AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has received test results from North-West University that indicate that Plandai's Phytofare(TM) Catechin Complex, which is derived from green tea phyto-nutrients, contains 2.2 times the amount of catechins by weight when compared to generic green tea extracts.
Plandai Biotechnology, Inc. Announces Phytofare(TM) Catechin Complex Can Be Used as a Dietary Supplement Without Prior FDA Notification or Approval
Marketwire - Wed Jun 18, 7:55AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has received a legal opinion from the noted law firm of Hyman, Phelps & McNamara, P.C., the largest dedicated food and drug legal firm in the country, in which it was determined that Plandai will not be required to apply to the US Food and Drug Administration for approval to market and sell its Phytofare(TM) Catechin Complex as a dietary supplement. This opinion paves the way for Plandai to immediately commence sales efforts in the United States.
OTC Sector Trading Focus List: GrowBlox Sciences, Inc., Amarantus Bioscience Holdings, Inc., Plandai Biotechnology, Inc., Limitless Venture Group, Inc., Infinex Ventures, Inc.
PR Newswire Europe - Wed Jun 11, 5:30AM CDT
LONDON, June 2, 2014 /PRNewswire/ --
Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory
Marketwire - Tue Apr 01, 8:03AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has completed and successfully optimized Stage 2 of its state-of-the-art production facility on the Senteeko Tea Estate in South Africa. Section 2 is the critical stage of the factory's operations as it is in this section that the hydrodynamic sheering process takes place.
Confidential LOI Executed for Unprecedented 'Marijuana Index Fund' - Possible Retracement as The Marijuana Index Dips to $17.95 - 175,000 Jobs Added in February Per US Department of Labor
ACCESSWIRE - Mon Mar 31, 8:09PM CDT
March 31, 2014 / The Marijuana Index - the first and only equity tracking index for marijuana stocks, cannabis stocks, and hemp stocks featuring dynamic financial content, charts, and centralized press for public companies - experienced several significant (positive) events during an otherwise turbulent month (beware the Ides of March, indeed).
Plandai Biotechnology "Waiver" Could Dramatically Expedite Medical Marijuana Research
Marketwire - Mon Mar 31, 8:04AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL) has a real opportunity to advance its medical marijuana research, and in doing so, it could be one of the first publicly traded companies in the cannabis industry to reach clinical trials with the drug. While laws in the US still prohibit the advancement of research using marijuana due to its Schedule 1 classification, Plandai's interest in using the drug to discover promising treatments may be about to come to fruition. The company may owe this unexpected opportunity to relationships it has formed on an entirely different continent.
Plandai Biotechnology Management Discusses Progress of Company's Cannabis Extracts
Marketwire - Fri Mar 28, 8:01AM CDT
Last month Plandai Biotechnology, Inc. (OTCQB: PLPL) closed a licensing agreement with Diego Pellicer, Inc. that will allow the company to use the Diego Pellicer name for its Phytofare(TM) cannabis extract in medical and pharmaceutical marijuana applications. Plandai will produce the new Diego Pellicer Gold(TM) extracts in both capsules and cannabis oil (for vapor use) in Pheroid(TM) and non-Pheroid(TM) versions to appeal to the broadest range of medicinal consumers.
Plandai Biotechnology's Human Clinical Trials Offer Significant Proof of Concept
Marketwire - Wed Mar 26, 8:04AM CDT
What may have been lost in Plandai Biotechnology's (OTCQB: PLPL) recently reported results from its human clinical trial to test the anti-aging properties of Phytofare(TM), is that the "statistically significant" results are themselves extremely significant to the future of the company. First and foremost, the results delivered in this human trial using Plandai's Phytofare(TM) Catechin Complex show "proof of concept," and for investors, that proof should turn out to be no small thing when it comes to the future success of this company.
Plandai Biotechnology Reports Positive Human Clinical Trial Results on New Topical Cream
ACCESSWIRE - Mon Mar 24, 8:27AM CDT
Plandai Biotechnology Inc.'s (OTCQB: PLPL), a company that develops heath products from cannabis plant extracts, reported favorable results from a recent human clinical trial involving a topical preparation of its Phytofare(TM) Catechin Complex.
Plandai Biotechnology, Inc. Submits Request to South African Legislature to Permit Cannabis Research
Marketwire - Mon Mar 24, 8:02AM CDT
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced the submission of a request for ministerial dispensation to the Secretary of Parliament of South Africa to permit cannabis research in South Africa for medicinal purposes. Dr. Mario Oriani-Ambrosini, a South African legislator battling terminal cancer, recently introduced legislation to permit medical marijuana research and usage that has generated a groundswell of popular support and led to the formation of The Cancer Treatment Campaign.
